Company profile
Indivior Pharmaceuticals Inc
NASDAQ: INDV · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ North Chesterfield, VACIK 0001625297Reports USD
#139 of 1,418 Healthcare companies by revenue48th-percentile growth
EA Score
67BFH 77DQ 51GM 64SS 77
v0.1 · 65/100 weight · provisional
↑ return on assets, filing timeliness · ↓ disclosure history, balance-sheet leverage
Methodology →Revenue TTM
$1.3B
Rev growth YoY (TTM)
+10.2%
Net income (FY)
$210.0M
Employees
833
as of 2026-08-07
Market cap
$4.8B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.2B$1.2B2025
Net income$210.0M$210.0M2025
Operating income$262.0M$262.0M2025
Total assets$1.2B$1.2B2025
Liabilities$1.3B$1.3B2025
Equity-$98.0M-$98.0M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Indivior Pharmaceuticals Inc’s revenue?
Indivior Pharmaceuticals Inc booked $1.2B in FY2025 revenue, growing 4.3% year over year — about the middle of the pack among Healthcare companies we track, at a 16.9% net margin.
Peers · Healthcare
Progyny, Inc.71BTempus AI, Inc.59CCuraleaf Holdings, Inc.49DBio-Techne Corporation85AExtendicare Inc.79B+Omnicell, Inc.78B+Key facts
CEOJoseph J. Ciaffoni
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNorth Chesterfield, VA
ExchangeNASDAQ: INDV
Employees833
IPO date2014-12-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.